NasdaqCM:MEIP

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. More Details


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has MEI Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MEIP's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.3%

MEIP

4.0%

US Biotechs

3.9%

US Market


1 Year Return

73.3%

MEIP

39.5%

US Biotechs

18.5%

US Market

Return vs Industry: MEIP exceeded the US Biotechs industry which returned 39.7% over the past year.

Return vs Market: MEIP exceeded the US Market which returned 17.2% over the past year.


Shareholder returns

MEIPIndustryMarket
7 Day3.3%4.0%3.9%
30 Day19.5%1.5%-4.3%
90 Day-10.6%-3.0%8.1%
1 Year73.3%73.3%42.0%39.5%21.2%18.5%
3 Year20.0%20.0%15.3%9.7%38.2%29.0%
5 Year83.5%83.5%23.5%14.6%84.3%63.4%

Price Volatility Vs. Market

How volatile is MEI Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MEI Pharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: MEIP ($3.12) is trading below our estimate of fair value ($28.52)

Significantly Below Fair Value: MEIP is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: MEIP is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MEIP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MEIP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MEIP is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (3.4x).


Next Steps

Future Growth

How is MEI Pharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

67.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MEIP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MEIP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MEIP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: MEIP's revenue (46.8% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: MEIP's revenue (46.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MEIP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has MEI Pharma performed over the past 5 years?

-11.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MEIP is currently unprofitable.

Growing Profit Margin: MEIP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MEIP is unprofitable, and losses have increased over the past 5 years at a rate of 11.5% per year.

Accelerating Growth: Unable to compare MEIP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MEIP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).


Return on Equity

High ROE: MEIP has a negative Return on Equity (-58.83%), as it is currently unprofitable.


Next Steps

Financial Health

How is MEI Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: MEIP's short term assets ($208.6M) exceed its short term liabilities ($23.3M).

Long Term Liabilities: MEIP's short term assets ($208.6M) exceed its long term liabilities ($108.2M).


Debt to Equity History and Analysis

Debt Level: MEIP is debt free.

Reducing Debt: MEIP has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable MEIP has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: MEIP is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 0.9% per year.


Next Steps

Dividend

What is MEI Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MEIP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MEIP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MEIP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MEIP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MEIP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average management tenure


CEO

Dan Gold (66 yo)

10.42yrs

Tenure

US$1,854,414

Compensation

Dr. Daniel P. Gold, also known as Dan, Ph.D. has been the Chief Executive Officer and President of MEI Pharma, Inc. (Alternate Name: Marshall Edwards Inc.), a subsidiary of Novogen Limited since April 26, ...


CEO Compensation Analysis

Compensation vs Market: Dan's total compensation ($USD1.85M) is about average for companies of similar size in the US market ($USD1.96M).

Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Gold
President10.42yrsUS$1.85m0.33%
$ 1.2m
Brian Drazba
CFO & Secretary3.42yrsUS$842.61k0.033%
$ 117.0k
David Urso
COO & General Counsel2.17yrsUS$1.31m0.021%
$ 75.2k
Robert Mass
Chief Medical Officer9.25yrsUS$674.28k0.030%
$ 105.0k
David Walsey
Vice President of IR & Corporate Communicationsno datano datano data
Brian Powl
Senior VP of Marketingno datano datano data
Karen Potts
Senior Vice President of Regulatory Affairs5.92yrsno datano data
Richard Ghalie
Senior Vice President of Clinical Development4.5yrsno datano data

5.2yrs

Average Tenure

60.5yo

Average Age

Experienced Management: MEIP's management team is seasoned and experienced (5.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Daniel Gold
President10.42yrsUS$1.85m0.33%
$ 1.2m
Tamar Howson
Independent Non-Executive Director1.17yrsno data0%
$ 0
Frederick Driscoll
Independent Non-Executive Director2.58yrsUS$158.94k0.056%
$ 195.0k
Nicholas Glover
Independent Non-Executive Director7.25yrsUS$166.44k0%
$ 0
Kevan Clemens
Independent Non Executive Director5.75yrsUS$161.44k0%
$ 0
Christine White
Independent Non-Executive Chairman4.75yrsUS$183.94k0.013%
$ 46.8k
Thomas Reynolds
Independent Non-Executive Director7.58yrsUS$161.44k0.0089%
$ 31.2k
Charles Baltic
Independent Non-Executive Director8.92yrsUS$168.94k0.026%
$ 92.4k
Cheryl Cohen
Non-Executive Director0.42yrno datano data

5.8yrs

Average Tenure

66yo

Average Age

Experienced Board: MEIP's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.8%.


Top Shareholders

Company Information

MEI Pharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MEI Pharma, Inc.
  • Ticker: MEIP
  • Exchange: NasdaqCM
  • Founded: 2000
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$351.069m
  • Shares outstanding: 112.52m
  • Website: https://www.meipharma.com

Number of Employees


Location

  • MEI Pharma, Inc.
  • 11455 El Camino Real
  • San Diego
  • California
  • 92130
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MEIPNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDDec 2003
MMIADB (Deutsche Boerse AG)YesCommon StockDEEURDec 2003
0JW9LSE (London Stock Exchange)YesCommon StockGBUSDDec 2003

Biography

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase de ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/01 00:08
End of Day Share Price2020/09/30 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.